Incidence of aortic stenosis in subjects with normal and slightly elevated aortic gradients and flow
ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort stud...
Saved in:
Published in | Heart (British Cardiac Society) Vol. 101; no. 23; pp. 1895 - 1900 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
01.12.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 1355-6037 1468-201X 1468-201X |
DOI | 10.1136/heartjnl-2015-307807 |
Cover
Loading…
Abstract | ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5–9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10–15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years. |
---|---|
AbstractList | We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.
Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).
At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.
The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years. ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5–9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10–15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years. We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.OBJECTIVEWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).METHODSParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.RESULTSAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.CONCLUSIONSThe results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years. ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsoe Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient greater than or equal to 15mmHg or a peak flow exceeding 2.6m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10mmHg) and peak aortic flow (cut-off 1.5 and 2m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9mmHg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9mmHg and in 0.3% of those with a gradient <5mmHg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7mmHg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10-15mmHg or aortic flow >2.0m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7years. Objective We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease. Methods Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient â[per thousand]¥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s). Results At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year. Conclusions The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years. |
Author | Rasmussen, Knut Heggelund, Geir Eveborn, Gry Wisthus Schirmer, Henrik |
Author_xml | – sequence: 1 givenname: Gry Wisthus surname: Eveborn fullname: Eveborn, Gry Wisthus email: gry.eveborn@unn.no organization: Division of Cardiothoracic and Respiratory Medicine, Department of Heart Disease, University Hospital of Northern Norway, Tromsø, Norway – sequence: 2 givenname: Henrik surname: Schirmer fullname: Schirmer, Henrik email: gry.eveborn@unn.no organization: Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway – sequence: 3 givenname: Geir surname: Heggelund fullname: Heggelund, Geir email: gry.eveborn@unn.no organization: Division of Cardiothoracic and Respiratory Medicine, Department of Heart Disease, University Hospital of Northern Norway, Tromsø, Norway – sequence: 4 givenname: Knut surname: Rasmussen fullname: Rasmussen, Knut email: gry.eveborn@unn.no organization: Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26531820$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtr3TAQRkVJaB7tPyhF0E03TiRLtuzuSkjbQCCbFrozeoxyZWQpleSE_PvocnO7yCZZjRjOmUHznaCDEAMg9ImSM0pZf74BmcocfNMS2jWMiIGId-iY8n7Ytv4e1DfruqYnTByhk5xnQggfh_49Omr7jtGhJcfIXAXtDAQNOFosYypO41wgxOwydgHnVc2gS8YPrmxwiGmRHstgcPbudlP8IwYP97KA2du3SRoHoSpbzPr48AEdWukzfHyup-jPj8vfF7-a65ufVxffrxvFyVAaPVrLDaO6ZVwZOWjopFGqtyNoK6QeW8Gl7pTWyhpFtSAgRq46xUbKiWzZKfq6m3uX4r8VcpkWlzV4LwPENU90IEMvOjp0r6OCMTr2TIiKfnmBznFNoX6kUvXonPKRV-rzM7WqBcx0l9wi0-O0P3UF-A7QKeacwP5HKJm2iU77RKdtotMu0ap9e6FpV2RxMZQknX9NPt_Japnftu4Jsn-52w |
CitedBy_id | crossref_primary_10_1111_echo_14270 crossref_primary_10_1080_14017431_2016_1239837 crossref_primary_10_1136_heartjnl_2021_319697 crossref_primary_10_1136_openhrt_2021_001783 crossref_primary_10_3389_fcvm_2023_1170804 crossref_primary_10_1002_ehf2_13957 |
Cites_doi | 10.1016/S0002-9149(98)00922-9 10.1016/S0002-9149(98)01064-9 10.1007/s10654-014-9936-x 10.1093/ije/dyr049 10.1136/heartjnl-2012-302265 10.1093/ejechocard/jen303 10.1161/CIRCULATIONAHA.104.486738 10.1016/j.jacc.2007.07.064 10.1016/S0735-1097(96)00563-3 10.1111/j.1365-2796.2011.02480.x 10.1161/CIRCULATIONAHA.106.176857 10.1001/archinte.162.20.2345 10.1016/0735-1097(93)90249-Z 10.1093/eurheartj/ehs109 10.1016/S0002-9149(02)03011-4 10.1136/hrt.54.4.396 |
ContentType | Journal Article |
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing |
Copyright_xml | – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing – notice: Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88I 8AF 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0S M1P M2P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7X8 7QO 8FD FR3 P64 |
DOI | 10.1136/heartjnl-2015-307807 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central BMJ Journals ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE MEDLINE - Academic Engineering Research Database ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-201X |
EndPage | 1900 |
ExternalDocumentID | 4021187441 26531820 10_1136_heartjnl_2015_307807 heartjnl |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .VT 0R~ 29I 2WC 354 39C 3O- 4.4 40O 53G 5GY 5RE 7X7 7~S 88E 88I 8AF 8FI 8FJ 8R4 8R5 AAFWJ AAHLL AAKAS AAOJX AAWJN AAWTL AAYEP ABAAH ABJNI ABKDF ABMQD ABOCM ABUWG ABVAJ ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADUGQ ADZCM AEKJL AENEX AFFNX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZFZN AZQEC BAWUL BCR BENPR BLC BLJBA BOMFT BPHCQ BTHHO BVXVI C1A CAG CCPQU COF CXRWF DIK DU5 DWQXO E3Z EBS EJD EX3 F5P FEDTE FYUFA GNUQQ GX1 H13 HAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H L7B M1P M2P N4W N9A NTWIH NXWIF O9- OK1 OVD P2P PCD PEA PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UKHRP UYXKK V24 VM9 WH7 WOQ WOW X7M YFH YQY ZGI ZXP AAYXX ACQHZ ADGHP AERUA CITATION PHGZM CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI Q9U 7X8 PUEGO 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-b408t-c9ff4d31c234bda8ce5adbb6f9ecf7ac9274ac5bccbfdb1c70e794b5b39140a23 |
IEDL.DBID | 7X7 |
ISSN | 1355-6037 1468-201X |
IngestDate | Fri Sep 05 05:23:09 EDT 2025 Thu Sep 04 16:39:54 EDT 2025 Sat Jul 26 02:40:11 EDT 2025 Thu Apr 03 07:05:57 EDT 2025 Thu Apr 24 22:57:48 EDT 2025 Tue Jul 01 04:32:17 EDT 2025 Thu Apr 24 22:50:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 23 |
Language | English |
License | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b408t-c9ff4d31c234bda8ce5adbb6f9ecf7ac9274ac5bccbfdb1c70e794b5b39140a23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 26531820 |
PQID | 1780741494 |
PQPubID | 2041068 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1808675185 proquest_miscellaneous_1733196377 proquest_journals_1780741494 pubmed_primary_26531820 crossref_primary_10_1136_heartjnl_2015_307807 crossref_citationtrail_10_1136_heartjnl_2015_307807 bmj_primary_10_1136_heartjnl_2015_307807 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20151200 2015-12-01 2015-Dec 20151201 |
PublicationDateYYYYMMDD | 2015-12-01 |
PublicationDate_xml | – month: 12 year: 2015 text: 20151200 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Heart (British Cardiac Society) |
PublicationTitleAlternate | Heart |
PublicationYear | 2015 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
References | Bodegard, Skretteberg, Gjesdal 2012; 271 Lindroos, Kupari, Heikkila 1993; 21 Stewart, Siscovick, Lind 1997; 29 Eveborn, Schirmer, Heggelund 2013; 99 Baumgartner, Hung, Bermejo 2009; 10 Singh, Evans, Levy 1999; 83 Novaro, Katz, Aviles 2007; 50 Freeman, Otto 2005; 111 Faggiano, Antonini-Canterin, Erlicher 2003; 91 Bonow, Carabello, Kanu 2006; 114 Aronow, Ahn, Shirani 1999; 83 Eveborn, Schirmer, Lunde 2014; 29 Hegrenaes, Hatle 1985; 54 Jacobsen, Eggen, Mathiesen 2012; 41 Vahanian, Alfieri, Andreotti 2012; 33 Cosmi, Kort, Tunick 2002; 162 |
References_xml | – volume: 83 start-page: 599 year: 1999 article-title: Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis publication-title: Am J Cardiol doi: 10.1016/S0002-9149(98)00922-9 – volume: 83 start-page: 897 year: 1999 article-title: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) publication-title: Am J Cardiol doi: 10.1016/S0002-9149(98)01064-9 – volume: 29 start-page: 567 year: 2014 article-title: Assessment of risk factors for developing incident aortic stenosis: the Tromsø study publication-title: Eur J Epidemiol doi: 10.1007/s10654-014-9936-x – volume: 41 start-page: 961 year: 2012 article-title: Cohort profile: the Tromso study publication-title: Int J Epidemiol doi: 10.1093/ije/dyr049 – volume: 99 start-page: 396 year: 2013 article-title: The evolving epidemiology of valvular aortic stenosis. The Tromsø study publication-title: Heart doi: 10.1136/heartjnl-2012-302265 – volume: 10 start-page: 1 year: 2009 article-title: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice publication-title: Eur J Echocardiogr doi: 10.1093/ejechocard/jen303 – volume: 111 start-page: 3316 year: 2005 article-title: Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.104.486738 – volume: 50 start-page: 1992 year: 2007 article-title: Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.07.064 – volume: 29 start-page: 630 year: 1997 article-title: Clinical factors associated with calcific aortic valve disease. publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(96)00563-3 – volume: 271 start-page: 581 year: 2012 article-title: Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men publication-title: J Intern Med doi: 10.1111/j.1365-2796.2011.02480.x – volume: 114 start-page: e84 year: 2006 article-title: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.176857 – volume: 162 start-page: 2345 year: 2002 article-title: The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening publication-title: Arch Intern Med doi: 10.1001/archinte.162.20.2345 – volume: 21 start-page: 1220 year: 1993 article-title: Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(93)90249-Z – volume: 33 start-page: 2451 year: 2012 article-title: Guidelines on the management of valvular heart disease (version 2012) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs109 – volume: 91 start-page: 99 year: 2003 article-title: Progression of aortic valve sclerosis to aortic stenosis publication-title: Am J Cardiol doi: 10.1016/S0002-9149(02)03011-4 – volume: 54 start-page: 396 year: 1985 article-title: Aortic stenosis in adults. Non-invasive estimation of pressure differences by continuous wave Doppler echocardiography publication-title: Br Heart J doi: 10.1136/hrt.54.4.396 |
SSID | ssj0004986 |
Score | 2.2018325 |
Snippet | ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific... We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic... Objective We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific... |
SourceID | proquest pubmed crossref bmj |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1895 |
SubjectTerms | Adult Aged Aged, 80 and over Aorta - diagnostic imaging Aorta - physiopathology Aortic Valve - diagnostic imaging Aortic Valve - physiopathology Aortic Valve Stenosis - diagnosis Aortic Valve Stenosis - epidemiology Aortic Valve Stenosis - physiopathology Blood Flow Velocity Disease Disease Progression Echocardiography, Doppler, Color - methods Female Follow-Up Studies Health Surveys Hospitals Humans Medical prognosis Middle Aged Morphology Multivariate analysis Norway - epidemiology Older people Population Population Surveillance Proportional Hazards Models Survival analysis Velocity |
Title | Incidence of aortic stenosis in subjects with normal and slightly elevated aortic gradients and flow |
URI | https://heart.bmj.com/content/101/23/1895.full https://www.ncbi.nlm.nih.gov/pubmed/26531820 https://www.proquest.com/docview/1780741494 https://www.proquest.com/docview/1733196377 https://www.proquest.com/docview/1808675185 |
Volume | 101 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NaxUxEA-2BfEifvu0lggevITuviSbzUlUWorQImLh3ZZ8Ssuard33EP97Z7LZVzxYPe-EDZOZyW8myfwIeVNpr2VYNixqq5lQ0jNTu8CEiwI2OB-ixIfCp2fNybn4tJKrUnAby7XKOSbmQO0HhzXyw1ph2xbA8-Ld1Q-GrFF4ulooNHbIXm5dBvasVurmXaTOTI817KmsqbgqT-dq3hwiXfT6MvVgJbXEAkyLhLI79vvlnxvUX1Bn3n2OH5D7BTbS99M6PyR3QnpE7p6Wg_HHxIOfT_SgdIjUDChHYQHTMF6M9CLRcWOx4jJSLLzShEi1pyZ5CjgT0vP-F8WH5gA8_Tz623W-DQZDUCz2w88n5Pz46OvHE1YIFJgVVbtmTscoPK_dkgvrTeuCNN7aJurgojJOQ0pqnLTO2eht7VQVwD2ttFxD3mWW_CnZTUMKzwn1LQ-65pFDPilUC-GaV6aKDuCTsdpXC_IWdNddTS0yupxa8Kab1dyhmrtJzQvCZwV3rjQiRz6M_h-j2HbU__1lf167rrjl2N0Y0YK83n4Gh8JTEpPCsEEZnsOSUrfItJAJ4oGVXJBnk11sJ7VsIKwBrnpx-wReknvZ9PLNmH2yu77ehFeAb9b2IBvxAdn7cHT2-ctv8jD7jg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxRBEO7gkqgXgy9cBW0TTbx0mJnuefTBEFDIIuzGGEi4jf1EyDiDzGwIf8rfSNU8lngQvXCe7kyn-uuqr6q6ugh5F0grYxclzEstmUhjy1RoHBPGCzBw1vkYC4Wns2RyJL4cx8dL5PdQC4PXKged2CpqWxmMkW-EKT7bAnxebJ7_Ytg1CrOrQwuNDhb77uoSXLb6495n2N_3UbS7c_hpwvquAkyLIGuYkd4Ly0MTcaGtyoyLldU68dIZnyojwU9TJtbGaG91aNLAAWZ1rLkEZ0ThQweg8pcFVrSOyPL2zuzrt5tKTNn2lgzBirMk4GlfrBfyZAMbVDdnZQG4DGMM-WTYwvae_nn2p0n8C89t7d3uCnnUE1W61SHrMVly5RNyf9qn4p8SC5qla0hKK09VheMoQKas6tOanpa0nmuM8dQUQ720RG5cUFVaCsz25EdTXFEsbQeqa4fZJxft_TOYgsN8UV0-I0d3ItznZFRWpXtBqM24kyH3HDxYkWZgIHigAm-AsCktbTAmH0B2-Xn3KEfeOjM8yQcx5yjmvBPzmPBBwLnpnz7HDhzFP2axxaz_-8vasHd5rwjq_Aa2Y_J28RmOMOZlVOmqOY7hrSJM01vGZOB7YoosHpPVDheLRUUJKFJgci9vX8Ab8mByOD3ID_Zm-6_IwxaG7b2cNTJqLuZuHdhVo1_3kKbk-12fomvkyju- |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouqLy3LWAkkLhYm8RxHB8qhCirltKKA5X2FvwsrULSNllV_Wv9dczksRUHCpeeM1as8eeZb2zPDCFvI-WU8EnGgjKKpVI4pmPrWWpDCg7O-SAwUfjgMNs9Sr_MxXyFXI-5MPiscrSJnaF2tcUz8mkssWwL8Pl0GoZnEd92Zh_Ozhl2kMKb1rGdRg-RfX91CeFbs723A2v9Lklmn79_2mVDhwFm0ihvmVUhpI7HNuGpcTq3XmhnTBaUt0FqqyBm01YYa01wJrYy8oBfIwxXEJhoLHoA5v--5MCqYC_JubzJyVRdl8kY_DnLIi6HtL2YZ1NsVd2eViUgNBZ4-JNjM9t75tfpn87xL4y383yzdfJwoKz0Y4-xR2TFV4_J2sFwKf-EOLAxfWtSWgeqa5SjAJ6qbk4aelLRZmHwtKeheOhLK2TJJdWVo8Bxj3-25RXFJHcgvW4cfXzRvUSDISgWyvryKTm6E9U-I6tVXfkXhLqcexXzwCGWTWUOroJHOgoWqJs2ykUT8h50V5z15TmKLqzhWTGquUA1F72aJ4SPCi7sUAQde3GU_xjFlqP-7y9b49oVg0loihsAT8ib5WfYzHhDoytfL1CGdyZRyltkcohC8bJMTMjzHhfLSSUZmFTgdBu3T-A1WYO9U3zdO9zfJA86FHYPdLbIanux8C-BZrXmVYdnSn7c9Qb6DdXKPoU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+aortic+stenosis+in+subjects+with+normal+and+slightly+elevated+aortic+gradients+and+flow&rft.jtitle=Heart+%28British+Cardiac+Society%29&rft.au=Eveborn%2C+Gry+Wisthus&rft.au=Schirmer%2C+Henrik&rft.au=Heggelund%2C+Geir&rft.au=Rasmussen%2C+Knut&rft.date=2015-12-01&rft.eissn=1468-201X&rft.volume=101&rft.issue=23&rft.spage=1895&rft_id=info:doi/10.1136%2Fheartjnl-2015-307807&rft_id=info%3Apmid%2F26531820&rft.externalDocID=26531820 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6037&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6037&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6037&client=summon |